Abstract
Extensive clinical use has established beyond doubt the value of sulfapyridine and sulfathiazole in the treatment of pneumococcic pneumonia. Among the many similar compounds that have been synthesized, one in particular has shown sufficient promise in preliminary studies to be worthy of clinical trial. This compound, sulfadiazine (2-sulfanilamidopyrimidine) is the pyrimidine analogue of sulfapyridine, synthesized by Roblin and his associates. 1 Feinstone and his co-workers 2 administered sulfadiazine to various laboratory animals and obtained higher average blood levels than after the administration of similar dosages of sulfapyridine or sulfathiazole. The therapeutic effects with sulfadiazine were equal or superior to those with sulfapyridine or sulfathiazole, and the toxic reactions were less frequent. Studies on the absorption and excretion of sulfadiazine in human beings have been made by several groups of investigators 3 who agreed that higher levels of the drug in the blood were obtained and that these persisted over a
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
